0SAN.LSE Sandoz Group AG
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- 4.7%
- Dividend yield
- 2.10%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0SAN.LSE undervalued?
Graham numberThe Graham number of Sandoz Group AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sandoz Group AG fundamental analysis
No fundamental analysis for Sandoz Group AG yet.
Sandoz Group AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a str…
Full company profileSandoz Group AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sandoz Group AG annual financial statements
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 9.04B | 8.79B | 8.86B | 11.7B | 10.4B | 11.6B | 22.5B |
| Gross Profit | 4.16B | 4.15B | 4.15B | 5.33B | 4.93B | 5.46B | 10.5B |
| Operating Income | 1.34B | 1.38B | 1.33B | 438M | 307M | 1.72B | 3.17B |
| EBITDA | 1.38B | 1.83B | 1.57B | 1.00B | 742M | 2.29B | 4.38B |
| Net Income | 434M | 830M | 810M | 90.0M | 1.00M | 957M | 426M |
| EPS | 1.01 | 1.93 | 1.88 | 0.21 | 0.00 | 2.19 | 0.97 |
| Balance Sheet | |||||||
| Total Assets | 15.9B | 16.0B | 16.2B | 22.7B | 19.9B | 22.0B | 22.9B |
| Total Liabilities | 9.04B | 8.55B | 8.13B | 12.6B | 11.7B | 12.6B | 13.8B |
| Shareholders' Equity | 6.82B | 7.43B | 8.09B | 10.1B | 8.16B | 9.38B | 9.02B |
| Cash & Short-term Investments | 34.5M | 36.4M | 68.4M | 1.30B | 1.19B | 1.74B | 1.25B |
| Total Debt | 4.68B | 284M | 309M | 5.32B | 4.85B | 5.68B | 6.22B |
| Cash Flow | |||||||
| Operating Cash Flow | 1.03B | 1.24B | 1.17B | 423M | 656M | 1.67B | 3.41B |
| Capital Expenditure | 310M | 382M | 408M | 730M | 596M | 516M | 1.04B |
| Free Cash Flow | 721M | 856M | 760M | -307M | 60.0M | 1.15B | 2.37B |
| Ratios | |||||||
| ROE | 6.4% | 11.2% | 10.0% | 0.9% | 0.0% | 10.2% | 4.7% |
| ROA | 2.7% | 5.2% | 5.0% | 0.4% | 0.0% | 4.3% | 1.9% |
| Net Profit Margin | 4.8% | 9.4% | 9.1% | 0.8% | 0.0% | 8.2% | 1.9% |
| Debt to Equity | 0.69x | 0.04x | 0.04x | 0.53x | 0.59x | 0.61x | 0.69x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sandoz Group AG dividends
- Dividend yield
- 2.10%
- Forward dividend
- -
- Payout ratio
- 34.5%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 330M | 0.76 | 34.5% |
| 2024 | 215M | 0.50 | 21,500.0% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sandoz Group AG
- Insiders 4.19%
- Institutions 53.55%
- Public & others 42.27%
- Free float 416M
Sandoz Group AG company profile
- Company name
- Sandoz Group AG
- Ticker
- 0SAN.LSE
- ISIN
- CH1243598427
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 20,000
- Fiscal year end
- December
- Address
- Centralbahnstrasse 4, Basel, Switzerland, 4051
- Phone
- 41 61 324 11 11
- Website
- sandoz.com
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Sandoz Group AG management
10- Mr. Richard SaynorChief Executive Officer · born 1967
- Mr. Remco J. SteenbergenChief Financial Officer · born 1968
- Mr. Asaf GalChief Technology Officer · born 1969
- Ms. Claire D'Abreu-HaylingChief Scientific Officer & President of Generics Development · born 1964
- Mr. Craig MarksHead of Investor Relations
- Ms. Ingrid SollererGeneral Counsel & Chief Compliance Officer · born 1974
- Ms. Tripti JhaChief People Officer · born 1977
- Dr. Glenn A. Gerecke Ph.D.Chief Manufacturing & Supply Officer · born 1959
- Ms. Rebecca GunternChief Commercial Officer · born 1972
- Ms. Keren HaruviPresident of North America · born 1980